In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.

Kura Oncology Inc. (NASDAQ:KURA) is one of the stocks that will double in 2026. On November 24, Barclays analyst Etzer Darout raised the firm’s price target on Kura Oncology to $28 from $11 and ...

PM ETSAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, ...

A new study published in the Journal of American Medical Association showed that reduced right ventricular ejection fraction ...

Azacitidine and decitabine belong to a class of antineoplastic agents known as DNA methyltransferase inhibitors (DMTIs). Each is paired with cedazuridine, a cytidine deaminase inhibitor, to help the ...

Guidelines recommend older adults with newly diagnosed AML should be offered antileukemic therapy over best supportive care.

A chemotherapy-free regimen significantly improved outcomes compared with standard therapy for newly diagnosed Ph+ acute ...

Removing etoposide did not negatively affect OS, DFS, MRD, or relapse rate at 3 years for pediatric patients with LR1, LR2 or high-risk AML.

In November 2025, the U.S. Food and Drug Administration (FDA) issued several approvals across oncology and supportive care.

The latest update is out from Race Oncology Ltd. ( (AU:RAC) ).

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...